In the PEARL trial (114 people, 5-10 mg/week for 48 weeks), rapamycin was well tolerated with a modest signal in women at 10 mg (lean mass, pain); the compounded form was poorly absorbed.
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).